INS and type 1 diabetes mellitus: In summary, while novel therapies that restore β-cell mass are required to effectively ameliorate deficiencies associated with insulin-dependent diabetes, our study serves as a proof of concept that EZH2 inhibition could influence reprogramming of adult human pancreatic ductal cells towards insulin expressing and glucose responsive β-like transitioning cells following 48 h of exposure to inhibitors.